NSEGeneral Updates8 Oct 2026 · 8 Oct 2026, 07:22 pm

General Updates

Aarti Drugs Limited · AARTIDRUGS

✦ AI SummaryESG

Aarti Drugs Limited has informed the Exchange about Crisil ESG Rating, which has assigned an Environmental, Social, and Governance (ESG) Rating of 'Crisil ESG 61' (Strong) for the Company based on the data pertaining to FY 2025-26.

Analysis Scores

Earnings Impact1/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Aarti Drugs Limited has informed the Exchange about Crisil ESG Rating

Attachments (1)

📄

AARTIDRUGS_08102026191926_AARTIDRUGS.pdf

pdf

Download →
View document text
Ref: ADL/SE/2026-27/53 October 8, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Sub: Crisil ESG Rating Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we would like to inform you that Crisil ESG Ratings & Analytic Limited (Crisil ESG Ratings), a SEBI registered Category-1 ESG Rating Provider, vide its report received by the Company on October 7, 2026, has assigned an Environmental, Social, and Governance (ESG) Rating of ‘Crisil ESG 61’ (Strong) for the Company based on the data pertaining to FY 2025-26. Please note that the Company has not engaged Crisil ESG Ratings for ESG Rating. Crisil ESG Ratings has independently prepared the report based on data pertaining to FY 2025-26 of the Company available in public domain. This disclosure is in compliance with Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular SEBI/HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026. You are requested to take the same on records. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932